Biopharmaceutical entrepreneurship in two Japanese and French bioclusters: differences in founder profiles and experience by Jolivet, Eric et al.
Biopharmaceutical entrepreneurship in two Japanese
and French bioclusters: differences in founder profiles
and experience
Eric Jolivet, Caroline Lanciano-Morandat, Hiroatsu Nohara, Daniel Pardo
To cite this version:
Eric Jolivet, Caroline Lanciano-Morandat, Hiroatsu Nohara, Daniel Pardo. Biopharmaceutical
entrepreneurship in two Japanese and French bioclusters: differences in founder profiles and
experience. Asian Business and Management, Palgrave Macmillan, 2009, 8 (4), pp.429-460.
<halshs-00424901>
HAL Id: halshs-00424901
https://halshs.archives-ouvertes.fr/halshs-00424901
Submitted on 26 Nov 2011
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
 
Bio-pharmaceutical entrepreneurship in two Japanese and French bio-
clusters: differences in founder’s profiles and experience. 
 
27th of May 2009 
Draft version – Please do not quote without permission of authors 
 
*Eric Jolivet, University of Toulouse, Graduate School of Management (IAE), Research in 
Management Centre (CRM-CNRS), 2, rue Doyen Marty, 31042 Toulouse Cedex 09 France 
Eric.jolivet@iae-toulouse.fr 
Caroline Lanciano, LEST-CNRS (UMR 6123), 35 avenue Jules Ferry 13100 Aix en Provence, 
France  
Hiroatsu Nohara, LEST-CNRS (UMR 6123), 35 avenue Jules Ferry 13100 Aix en Provence, 
France 
Daniel Pardo, LEST-CNRS (UMR 6123), 35 avenue Jules Ferry 13100 Aix en Provence, 
France 
 
 
 
 
Paper submitted to Asian Business Management, Special Issue on Cultures Meet Technology 
  
 Abstract: 
Favoured by genetic engineering breakthroughs, a new type of firm has emerged in the pharmaceutical 
industry, called the New Biotechnology Firm (NBF). NBFs are ‘bridging institutions’ as they accelerate 
the commercialisation of science from academia to the pharmaceutical market and facilitate technological 
incursions into drug development or therapeutic paths yet unexplored and as such, have raised particular 
industrial and political interest around the world. Successes are, however, outstanding in the NBF world 
and some countries seem to offer much more favourable environments than others. Countries 
performances are usually benchmarked against their provision of favourable resources and institutions: 
patent rights, venture capital, dedicated stock market, skilled human resources. This paper takes an 
alternative route by considering the entrepreneurial side of NBF emergence: founders/entrepreneurs 
experience and incentives to create NBFs as a major factor of the emergence of these bridging institutions.  
To do so, ‘entrepreneur’s biographies’ and their firm creation experience were collected in two 
comparable bio-clusters in France (Evry) and Japan (Kobe) on 11 Japanese and French drug 
development NBFs. The result shows an interesting variation in entrepreneurs’ backgrounds and 
motivations across countries in that almost all of our French entrepreneurs came from public research 
institutes whereas a large share of our Japanese entrepreneurs came from large pharmaceutical 
companies. This finding questions the universal nature of entrepreneurship in bio-pharmaceutical firms 
and invites consideration for a model of entrepreneurship that is socially embedded in a country’s specific 
institutional and historical factors. 
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 Introduction 
 
The drug development business has experienced a tremendous transformation in the last 20 
years. As this industry became gradually more concentrated around a handful of very large 
multinational pharmaceutical companies, the creative part of drug discovery was increasingly 
taken over by a new type of small bio-pharmaceutical firm, called a New Biotechnology Firm 
(NBF).  
 
These ‘science based’ entrepreneurial ventures have been considered as an emerging hybrid 
organisational form between universities and large industrial companies, aimed at accelerating 
and diversifying the process of drug innovation. They are exploring and facilitating the 
transfer of new therapeutic paths and new compounds – based on biotechnologies - from 
prominent university researchers that invented them to the industry. They are novel 
intermediaries, or ‘bridging institutions’ between university research and large pharmaceutical 
companies (Gans and Stern 2003), and as such, now represent a major source of innovative 
drugs drugs (Cokburn and Henderson 1998).  
  
Gene therapy, cell therapy, and tissue culture are amongst the promising new approaches to 
diseases — such as diabetes, HIV, cancers, cardio-vascular diseases or muscular dystrophy — 
explored by these start up firms that unsurprisingly attracted important economic and political 
interests around the world (Lehrer et al. 2004, Casper this Volume).  
 
Most observations and analysis, so far, are based on the US experience where the NBFs 
model originated. The question of how this model was exported and adapted to different 
institutional contexts has recently attracted more attention (Gittelman 2006, Casper 2006). 
  International comparisons have stressed important disparities between countries in terms of 
the speed it takes to adopt these ‘bridging institutions’, as well as the ability to generate such 
new forms of organisation. Specifically, despite their renowned academic research, Japan and 
France seem to be performing poorly (Lehrer et al. 2004, Kneller 2007, Ernst and Young 
2007).  
 
Explanations for these disparities have generally been found in the more or less favourable 
environments provided. A number of ingredients have been considered necessary for growing 
NBFs with success. Advancement of academic research, favourable intellectual property, 
maturity of the national venture capital industry, and the existence of a dedicated stock market 
are amongst the ingredients found crucial by many experts (Kortum et al. 2000, Mustar 2001; 
Casper 2006).  
 
In this paper, we would like to take a new angle to compare country-level differences, one 
that would stress the role of NBF entrepreneurship sources and incentives as a major 
discrimination factor between countries.  
 
Relying on the national innovation system framework (Freeman 1987), we claim that NBF, as 
bridging institutions, are embedded into specific national organisational arrangements that 
need consideration. Accordingly, different roles are played by universities, large and small 
pharmaceutical companies and start up companies in biomedical innovation depending on the 
country considered (Kneller 2007). In this perspective, NBF creation should be considered 
both as an entrepreneurial action and as an organisational and institutional rearrangement of 
the existing national innovation systems. Who are entrepreneurs and where do they come 
 from? How do they capture technological opportunities? How do national contexts influence 
their profiles and careers? 
 
So far, very limited comparative studies are available to support or discard this view and more 
empirical support is needed. This paper reports on such a study aiming at contributing to 
filling this knowledge gap. It explores the links between the relatively poor performance of 
Japan and France in terms of NBF creation in relation to the sources and incentives of NBF 
entrepreneurship. Therefore, we compared NBF entrepreneur’s biographies, strategies, and 
motivations to create an NBF in the two countries and linked them to specific features of 
Japan and France national systems of innovation. National systems of innovation are defined 
as ‘the networks of institutions in the public and private sectors whose activities and 
interactions initiate, import, modify, and diffuse new technologies’ (Freeman 1987). More 
broadly, the perspective adopted consist in considering that the innovative performance of 
firms in a particular country, depend on the manner in which a variety of actors (small and 
large firms, educational and research institutions like universities and research institutes, 
customers) interact to create new knowledge and innovations. Japan was shown as a country 
enjoying a highly efficient innovation system based mainly on the integrative role of large 
private companies supported by strong industrial policies coordinated by MITI (Freeman 
1987). France was described as a fairly centralised nation, organized around a major divide 
between basic research and technology development mainly promoted by public research 
institutes, and the commercial exploitation by national-champion type large companies 
(Chesnais 1993)  
 
We sampled our NBF companies in two comparables clusters, Every near Paris, and Kobe, on 
Japan’s Midwestern coast. In depth interviews were conducted with 20 business founders in 
 these two bio-clusters for a total sample of 11 companies. Additional data about the 
companies, in terms of the clusters and the respective national policies implemented in France 
and Japan during the period of observation, was collected for comparative purposes. 
 
The profiles and entrepreneurs’ experience in our Japan and France samples exhibit 
contrasting results and delineate identifiable careers in the two cases. It supports our claim 
that NBF creation be understood as one new organization finding its place in the wider 
existing national system of innovation.  
 
The paper is divided in four main parts. The first part situates NBF in the literature and shows 
that NBF creation has become an issue of international country comparison. Introducing the 
national innovation perspective, we argue that entrepreneur’s profile and experience are at the 
heart of country-specific new biomedical innovative arrangements. By profile we refer to 
human capital categories i.e. the background and professional experience. The second section 
describes the research methodology used in our research project, and describes both our 
sampling process in Japan and France and the variables we considered to characterise 
founders. Section three discloses the main findings of our research and compares NBF’s 
entrepreneur’s profiles and experience in our France and Japan samples. The contrasted 
results found and their implications are then discussed in the final part of the text.  
  
 I – Biotech Entrepreneurs in international perspective 
 
In this paper, we are focusing on biotech entrepreneurship in the field of drug and new 
therapy development. Although this share varies with countries, of the estimated 4203 
biotechnology firm population in the world in 2005, roughly half are so-called ‘red biotech’, 
dedicated to the health sector (Ernst & Young 2005). Among them, some are developing 
platform technologies and others are dedicated to drug discovery and new therapy (Casper 
2006).  Drug and therapy discovery oriented firms are intensively science-based, and are 
strategically of considerable importance to the pharmaceutical industry: while pharmaceutical 
R&D experiences an historical loss of productivity, an estimated 20% of new drugs already 
come from these firms and experts anticipate they would reach 40% by 2010 (Ernst & Young 
2006). They are representing crucial opportunities for large pharmaceutical firms worldwide.  
 
The ways in which these opportunities were seized in different countries seems, however, to 
be very variable. In this section, we review and discuss the literature then propose an 
approach focusing on the sources of entrepreneurship, the knowledge capture mechanisms, as 
well as the motivations of entrepreneurs, all questions which are lacking comparative 
perspectives. 
 
 
 
  
 A) Biotech entrepreneurs as key figures in the new drug R&D 
 
1) New Biotech firms as key players in the new pharmaceutical industry organisation 
 
In the drug sector, as we have seen, a recent and striking occurrence has been the emergence 
of New Biotechnology Firms (Malerba et al. 2002). As large pharmaceutical firms’ R&D-
based exploitation strategies seem to meet productivity limits, biotech startups propose new 
therapeutic approaches, more targeted drug design processes, and a new model for funding 
radical innovation (Galambos et al. 1998).  
 
Many experts estimate that these NBFs represent a great creativity potential to renew aging 
large firms’ portfolios and to explore unique and original technological paths efficiently. 
Some authors argue that NBFs are more efficient at the creativity part of drug discovery, 
whereas large pharmaceutical firms continue controlling the clinical, regulatory and 
marketing aspects (Cockburn et al. 1998).  
 
In this respect, it is not surprising that NBFs have garnered so much attention on the part of 
policy makers who have tried to set favourable conditions for their emergence. Important 
institutional reforms have been undertaken such as University re-organization, Intellectual 
property laws changes, as well as thorough industrial policies encouraging business creation 
and academic spin off in the biomedical sector. Pharmaceutical firms and university 
researchers have equally been attracted by the opportunities offered. Most reflections on NBF 
are based on the US case, where this model emerged. Recently, several authors investigated 
the manner in which this model was adapted to a variety of institutional contexts (Ibata-Arens 
2005, Gittelman 2006, Casper 2006, Kneller 2007).  
  
 
2) Biotech entrepreneurship in international perspective 
 
Considerable investigations have been carried out in the last 20 years by academics to 
understand the specificities and key success factors of these knowledge-intensive firms, which 
are now quite well identified. As most of the NBF emergence occurred in the United States, 
particularly in a few well–endowed US areas such as California and Massachusetts, so too did 
academic investigations.  
 
International comparative studies have been undertaken recently to pinpoint large disparities 
in country performances and ability to generate such new forms of organisations   (Lehrer et 
al. 2004; Bozeman et al 2004, Kneller 2007, Ernst and Young 2005).  
 
Common explanations for cross-country variability include: the density of networks relations 
between universities (Powell et al. 1996), NBF and large pharmaceutical companies 
(Cockburn et al. 1998, Kneller 2003), the presence of advanced research labs and star 
scientists (Zucker et al. 1998, 2002), to the development of venture capital and dedicated 
stock markets (Kortum et al. 2000, Mustar 2001) and the set up of a favourable IP rights 
(Kneller 2003). Such analysis tend however to assume little variety in NBF firms and 
benchmark mutatis mutandis NBF creation and growth rates against a high profile US model 
(Mangematin et al. 2003).  
 
Interesting approaches have most recently emphasized the role and place of the country 
specific institutional contexts in which the NBF model was transferred as a significant 
 variable explaining cross-country performance (Lehrer et al. 2004, Ibata-Arens 2005, Casper 
2006, Gittleman 2006). For instance Casper, drawing on the theory of varieties of capitalism, 
has found that countries exhibiting liberal forms of capitalism (US/UK) offer more favourable 
environments to the emergence of biotech start up than Coordinated Market Economy forms 
(Germany/Japan) (Casper 2006). This research agenda suggests that international 
comparisons of NBF require in depth understanding of the specific institutional contexts in 
which they are located.  
 
The national system of innovation theory (Freeman 1995) offers another interesting 
framework, we believe, to carry out this agenda as it aims at understanding ‘major differences 
between countries in the ways in which they have organised and sustained the development, 
introduction, improvement and diffusion of new products and processes’ (Freeman 1995 p.19). 
This theory pays particular attention to the respective and complementary role played by 
major actors contributing to innovation (universities, Government labs, large and small firms, 
and also end-users) in relation with country specific institutional contexts. This framework 
would fruitfully be applied to situate NBF creation in their wider societal contexts.   
 
Close to this approach, one recent study has recently illustrated the variety of national 
arrangements in the biomedical field and the interest of articulating NBF organisations to 
country specific institutional arrangements (Kneller 2007). Carrying out such a well- 
documented comparative study, Kneller (Kneller 2007) demonstrated that the sources of 
biomedical innovation were not similar in the US and Japan, as the interplay and 
complementarities of large pharmaceutical, universities and start up firms differ in these two 
contrasted institutional contexts. He found that large pharmaceutical companie’s in-house-
R&D has been the major vessel in Japan’s effort to appropriate biotechnologies, breaking 
 away from the US model in which start ups and specially academic start ups have played the 
central role in biomedical progress (Kneller 2007).  
 
3) The sources and incentives of NBF entrepreneurship 
 
As Gompers and Lerner (2005) put it, there is now a large literature dealing with the success 
factors and the necessary resources for technology venture, but ‘much less understanding of 
how these venture capital-backed entrepreneurs come to be entrepreneurs in the first place’. 
An additional question concerns the mechanisms through which scientific discoveries are 
transformed into valuable commodities.  
 
In this paper, we consider NBF creation as an economic action ‘embedded’ in the wider 
societal context.  Our argument comprises three main lines.  
 
First, the mechanisms at play have a lot to do, we argue, with the uncertainty associated with 
NBF entrepreneurship and their perceived risks. Gompers and Lerner question of how and 
why some individuals venture into business creation even take a particular flavour 
considering how risky the business of NBF creation is (Pisano 2006). Why, then, would some 
individuals or group of individuals take a chance on running such a risky business? What are 
the incentives, positive or negative, leading them?  
 
It is possible to distinguish between risks of three different natures. The collective and 
institutional management of these risks deeply conditions entrepreneurship.  
1) There is a risk that we would call entrepreneurial, that is associated with the success or 
failure of the NBF and the subsequent loss or gain of personal capital involved. This is a 
 function of the sort of commitment chosen by NBF founders: how much of their personal 
resources they have committed, how much ownership and control they retain in the firm, how 
much support they can get from their original organisation.   
2) There is a risk that we would call strategic. An NBF is a bet, this bet can lead to a 
successful innovative product or not, or at least to a successful exit or not. The commercial 
future of bio-venture products are marked by dynamic uncertainty (Casamatta 2003) and 
NBFs exhibit high rates of turnover (Powell et al. 1996, Pisano 2006). Many small 
biotechnology firms actually prefer to focus on platform technologies or to offer services than 
position themselves in the drug and new therapy discovery competition. This strategic risk 
depends to a large extent on the national system of biomedical research and innovation, 
particularly on the sort of synergies that start up firms would find with larger established 
companies.  
 
3) Finally, there is a career risk involved. Taking the lead or getting highly committed to one 
NBF might imply leaving a good safe position or not being as productive in ones original job. 
This risk relates to the rules and organisation of profession and careers in the biomedical 
sector.      
 
Our second line of argument regards founders to bridge the two worlds of science and 
industry, and articulate them within their country specific system of innovation. As Kneller 
convincingly demonstrated, sources of biomedical progress and innovation vary across 
countries (Kneller 2007). Entrepreneur’s origin should reflect such variations in national 
locus of biomedical innovations: in the US where research universities are prominent sources 
of biomedical innovations, academic entrepreneurship is most common (Shane 2004). 
Another complementary dimension associated with the locus of innovation regards knowledge 
 capture mechanisms (Zucker et al. 1998). How do founders organise access to and obtain 
property rights over valuable biomedical knowledge? The nature of knowledge involved in 
new products and therapies together with the rules of its appropriation condition how business 
founders elaborate capture mechanisms linking their companies to these sources. Rare and 
tacit knowledge characteristics of biomedical discoveries led U.S. NBF to closely enroll the 
most prominent scientists in their research field –  ‘star scientists’ -  (Zucker et al. 1998).  
 
The third line of argument relates to the peculiarities of the NBF activity. Start up creation 
requires a unique set of competence, strategic vision, and leadership to which no established 
career path generally prepares. So, the question of how entrepreneurs are recruited and trained 
is central as their competence extend to embrace a variety of heterogeneous dimensions. 
Entrepreneurs experience is thus an interesting variable to look at, as it should reflect how 
each particular country brings particular solutions to this problem. 
 
As a bridging institution, NBF need to bring together the two worlds of university research 
and pharmaceutical industry. In the past, pharmaceutical companies would somehow deal 
directly with university professors and labs in a more or less formal way. To be economically 
justified, NBF need to improve and ease the translation between these two worlds, in a way 
that universities or large firms alone would not or could not do. One interesting view 
considers NBF as a more favourable organisational setting for academic inventors to apply 
their discovery into a commercial concept than would be possible at university (Lehrer et al. 
2004). One key aspect relates to the creation of practicable career paths and labour markets. 
When such a market exists and is easily available, it provides an alternative for skilled people 
to industrial or administrative hierarchies and constitutes a source of independence and self 
achievement.  
  
II -  Research settings 
a) sample 
 
This study evaluates the influence of entrepreneur’s profiles and experience of company 
founders on the constitution of 11 NBF, 6 in France and 5 in Japan. This number being 
relatively small, we compared our data to larger national statistics on biomedical 
entrepreneurs in France and Japan to assess sample representativeness and the robustness of 
our results. General trends of our samples in terms of sources of innovation, origin of 
entrepreneur, performance of companies were confirmed to be very consistent with national 
data reported (JPO 2003, JBA 2005, 2006; France biotech 2007). More detailed discussion 
will be provided together with our results It was however difficult to find surveys detailed 
enough to provide global statistics on the origin and careers of NBF founders. In addition, 
both the institutional context and the industrial dynamics are quickly evolving in both 
countries in the biomedical sector. For instance, in Japan, strong emphasis was given to 
academic spin off in the last few years, and it will probably affect the balance of large 
company versus academic spin off in this country in the future.  
 
Table 1 compares a number of general characteristics of Japan and France biotech fields 
showing that the two countries profiles are comparables.  
 
 
[Table 1. overall picture of Japan and France biotech fields] 
 
 France and Japan share a number of common characteristics: a rather strict distinction 
between public and private research and careers, an excellent public research but with limited 
knowledge transfer to firms and commercial outcomes, important implication of a central 
state in economic coordination, relatively weak SME sector as compared with performing 
large global firms.   
 
France national system of innovation is historically characterized by importance of 
governmental labs and public research institutes as a major actor (Chesnay 1993). In addition 
to universities, governmental research centres and research institutes play a prominent role in 
research and notably basic research and technology development. The National Scientific 
Research Centre (CNRS) exemplifies this historical division between education and research 
oriented public organizations. In the biomedical fields, other public research institutes and 
governmental labs complement the CNRS (like the National Medical Research Institute 
‘INSERM’, Pasteur Institute, Gustave Roussy Institute and even the National Atomic Energy 
Centre ‘CEA’ that developed some health related research programmes).  Japan national 
system of innovation by contrast was structured around large companies integrating 
technological knowledge and creating technological knowledge through intensive in house 
R&D and strong links with manufacturing (Freeman 1987). 
 
The biotechnology ‘sector’ is made of very different realities and a wide variety of companies. 
For instance, its applications include products as different as cosmetics, seed and food, energy, 
drugs addressing fairly different markets. It was consequently our choice to focus our study 
on firms located in a similar industrial environment, namely biomedical start ups involved in 
drug discovery or new therapy development. We used a limited sample of firms for two 
reasons. First, considering our research objective to link NBF creation to the societal context, 
 data quality and data collection on biographies of founders and their experience of creation 
required in-depth qualitative interviews. Some 50 interviews of about one hour and a half 
each were conducted in France and in Japan by the research team with founders but also with 
‘context actors’ such as policy makers, public lab researchers, local authority representatives, 
cluster representative, venture capitalists involved with our 11 NBF founders. Second, for 
comparison purposes and consistency of our sample, we restricted ourselves to firms directly 
involved in biopharmaceutical R&D activities competing in the same industry and found in 
two comparable clusters. They were identified in limited number in the two clusters (some 10% 
of total firms) and a few of them did not reply to us.     
 
All firms sampled are situated in the same human drug and therapeutic products industry and 
are virtual competitors. For confidentiality reasons, we do not use actual person or company 
names, but call them by codes (for French NBF FE1, FE2, FE3, for Japanese NBF JE1, 
JE2…). For instance, J1 licensed in F1 therapeutic innovation. NBF have developed in a large 
number of sectors as their new products innovation have been applied to agriculture, 
veterinary, environment, and human health. In addition, bio-clusters are populated with small 
firms providing bio-material, medical instruments, equipments, services or devices to drug 
development companies. Besides, only SME’s with an entrepreneurial background and a 
strategic independence were included, excluding local affiliation and large company branches 
from our sample to retain only the ones with headquarters in our two clusters (Evry and Kobe). 
One exception is J3, which was created as a joint venture from a Japanese and an Australian 
NBF. Although R&D cooperation was intense between the two entities, J3 remained 
autonomous enough to have its own business creation history, and we decided to keep it in the 
sample. Finally, all our firms were in their early stage of development at the time of the 
interview. Interviews were conducted by researchers experienced in qualitative studies.  
  
All firms selected come from two bio-clusters: the Evry bio-cluster located near Paris, France 
(Jolivet 2001) and the Kobe bio-cluster in the Kansai area, Japan (Jolivet 2007). These two 
clusters are of comparable size (about 70 companies in Evry and 100 in Kobe) and are both 
considered amongst the most prominent in their respective countries (regrouping roughly one 
company on ten), and focused on new therapy and new drug development. Both clusters 
benefitted from important public funding and support both at the national and at the local 
level.  
  
 
b) Data and measures 
 
A number of independent variables, making the identity card of our sampled companies are 
disclosed in table 2a for the French NBF and 1b for the Japanese ones.  
 
Time of creation - The first important question regards the company year of creation. It is an 
important variable as regards the business creation and development of a company. Different 
phases of NBF development have been recognised to correspond to different needs in terms of 
human capital and resources: for example, in terms of financial counterparts, seed money, 
venture capital, investment banks usually succeed to one another (Casper 2006). Depending 
on the stage of maturity the NBF reaches, the focus of the company activity evolves from 
more scientific to more managerial (Bozeman et al. 2004, Murray 2004). A majority of new 
firms failing within their 3 first years of existence, surviving can already be considered an 
important achievement for NBF. Time not being precise enough to identify such phasing; we 
 considered another related variable, the number of employees. Together, they are used as a 
rough indicator of growth and maturity.  
 
In our study, we are interested in the influence of entrepreneurs in the very beginning of 
business creation. Date of creation is marking the very start of the NBF venture, a time of 
reference T0. During our study, we discovered that if the date of creation is indeed important, 
as from then on the innovative project gets a real corporate body, and a business existence, the 
creation time might not exactly represent the same situation in each company: in particular, 
pre-entrepreneurial phase might be more or less extensive. 
 
Technology and markets - The second set of variables we are considering are the technology 
used and the target ‘markets’ (in the pharmaceutical industry, the therapeutic classes). 
According to the literature, as we have seen, the very raison d’être of biopharmaceutical 
NBFs is to explore new paths and ways to approach drug development and diseases treatment. 
Together, technologies and markets are defining the arena for product competition. 
 
In terms of technology, a common distinction concerns radical and incremental innovations as 
they are relying on different learning processes. Another distinguishes between product and 
process innovations. We found them difficult to apply here. The categorisation introduced by 
Casper (2006) between platform and discovery based biotech proved more operational in our 
study. We interpreted discovery based as covering our full sample of drug discovery and new 
therapy discovery companies. Indeed, these companies distinguish themselves by taking in 
charge the upstream creative part of the drug discovery process. By contrast, we considered as 
platform companies, firms with only activity in supplying materials or services to drug 
discovery ones. This has strategic implications for the firm: when they are discovery oriented, 
 key factors of performance are a) leading the race to developing a new therapy and b) 
securing property rights to exploit this advantage commercially (Burton et al. 1999).  
 
Target markets or diseases are the second important variable in this framework. 
Biopharmaceutical ventures apply their embodied knowledge in a yet unexplored way to the 
drug/new therapy innovation process, or to a new target. It means that a variety of 
combinations are possible for differentiation. NBF mastering the same technologies might 
apply them to different targets or therapeutic classes. Conversely, one disease could be 
approached through different angles based on different technologies and scientific knowledge. 
Although a certain consistency between technology-product-market is certainly important for 
success, we have observed some flexibility in that respect on the part of the companies. 
Several of them had opportunistic and flexible behaviours as regards the acquisition of a 
technological body of knowledge and they diversified after a few years of existence. On the 
other hand, several changed or extended the number of targeted diseases for one particular 
technological path during their development process. The tables below are listing the French 
and Japanese companies in our sample and their main characteristics. 
 
[Table 1a - List of French NBF] 
 
[Table 1b - List of Japanese NBF] 
 
Table 1a and 1b show several elements. First, our sample is limited to 11 cases, which is 
relatively small. Justification for this choice is the important similarities of the firm studied in 
terms of technology, localisations and industry. All these factors have been demonstrated to 
be of influence on NBF studies (Stuart et al. 1999, Gompers et al. 2005). Our firms are 
 operating in the same field and with comparable industrial and regulatory environments, 
which makes it easier to analyse and compare how each company proceeds to attract valuable 
resources and how it affects their performance. In other words, the limited number of records 
in our sample is counterbalanced we hope by the control of a number of induced bias that 
would have been introduced confirms the comparability of the French and the Japanese 
sampled firms.  
 
c) Variables 
 
This study investigates three main questions: who are the business creators and where do they 
come from? How do they capture scientific knowledge and embody it into a commercial 
commodity or intermediary? How does this vary across countries?  
 
As we have seen, our comparative settings make it possible to compare our sampled French 
and Japanese companies ceteris paribus. In this section, we present the variables by which we 
will compare them. 
 
1) Entrepreneur’s origin 
 
1.1) Entrepreneur’s origin 
For most observers as well as for policy makers, considering the ‘science-based’ nature of 
NBF, they are likely to be established by academic-entrepreneurs (Lehrer et al. 2004, Shane 
2004). Inventors of scientific discoveries are indeed a natural source of NBF, as they might 
follow up their inventions to a more commercial stage.  
 Another view to the origin of entrepreneurs stresses the role of large established companies 
(Burton et al. 2002). Even though the authors recognise that rates of new venture spawning 
vary amongst them, they argue that the competence and reputation effects granted by such 
firms provide an important social capital (i.e. network of relations) to employees willing to 
become entrepreneurs (Burton et al. 2002).  
A third source of biotech ventures points to experienced entrepreneurs or entrepreneurial 
employees (Shane et al 2003). The San Diego cluster is a case in point (Casper 2007): it 
started with no tradition in commercial biotechnology and has become, after 27 years, one of 
the well established and recognised bio-clusters gathering some 120 NBF.  The author argues 
that although the original biotech company Hybritech commercially failed, it actually served 
as a backbone in the establishment of a developing networks of experienced managers that 
later irrigated current successful companies (Casper 2007).  
 
1.2) three categories of NBF entrepreneur’s origin 
From this, we retained three categories 1) academic-entrepreneurship 2) spin-off 
entrepreneurship (from large firms) 3) professional entrepreneurship (from other biotech 
firms). 
 
2) Knowledge capture mechanisms 
 
2.1) knowledge source 
This is a most common view to consider university as the source of knowledge for NBF 
creation (Zucker et al. 1998, Shane 2004). The logic beyond this view stands in the assumed 
‘science based’ nature of NBF, science being naturally sourced at universities. The meticulous 
work of Kneller (Kneller 2007) demonstrated this view as too simplistic as the locus of 
 biomedical innovation depends on country specific institutions: university centrality certainly 
holds in the US while large pharmaceutical and agro-food R&D produced significant basic 
research in Japan (Kneller 2007). In addition, governmental labs (or public research institutes) 
might occupy a prominent place in certain countries like France (Pasteur Institute, Gustave 
Roussy Institute, the CNRS, the INSERM) or to a lesser extent Japan (Riken).   
 
In our research, we are considering four categories of sources 1) Universities 2) 
Governmental Research Institute 3) Large pharmaceutical corporations R&D 4) Other firms 
R&D  
   
2.2) knowledge capture: mobility and commitment 
Knowledge source might be distinct from founder’s origin and background: we have observed 
several cases in which the founder of the company had a background in business management 
and sourced its medical and biological knowledge from universities and research institutes. It 
conducts us to emphasize the role of ‘knowledge transfers’, or more precisely the mechanisms 
through which firms get and appropriate valuable knowledge.  
 
There are two important characteristics of NBF knowledge base. First, as we are focusing our 
study on the creation stage of NBF, the knowledge base of the firm has to be sourced outside. 
Second, as we are talking of business firm commercialising novel products and therapies 
based on scientific and technological discoveries, valuable knowledge ought to be rare (small 
team of inventors), often tacit and difficult to transfer. This makes it excludable and 
appropriable (Zucker et al. 1998, 2002). One implication is that it often is embodied in the 
inventor and its close collaborators (Zucker et al. 1998). The question for firms is how to get 
an access to these people and their knowledge.  
 One well identified knowledge capture mechanism is inventor based entrepreneurship. In this 
case, scientists or their close collaborator follow on their discoveries to a commercial stage 
(Mangematin et al. 2002). Personal competence and relations are then transformed into 
human and social capital for the firm through scientist mobility (Murray 2004). 
Another capture mechanism consists in establishing collaborative ties with inventors. Direct 
training and contacts at bench level with inventors are considered as possible substitute to 
direct mobility (Zucker et al. 1998). 
Zucker has pointed to another essential aspect of the question, that of the level and form of 
commitment (Zucker et al. 1998). This aspect is we believe very relevant as modalities of 
mobility of inventors, as well as the nature of collaborative ties pertains on NBF knowledge 
base. For instance, in the US, a strong correlation has been found between the personal 
involvement of star scientists and the most successful NBF (Zucker et al. 1998).  
The following categories have been chosen 1) mobility of inventor 1a) complete mobility and 
leave from original institution 1b) part time mobility 2) status 2a) CEO 2b) CSO 2c) Board 
member 3) collaborative ties 3a) formal contracts 3b) informal links        
 
   
2.3) knowledge appropriation: patenting and complementary assets 
As we have just seen, the sort of knowledge base used by NBF is often rare, tacit and difficult 
to transfer in addition to be novel. This means that NBF might want to secure access to this 
knowledge and obtain some sort of exclusivity on its use is crucial in the perspective of future 
commercialisation. Patenting is considered an efficient appropriation mechanism in the 
pharmaceutical industry. Thus, patenting behaviour represents an interesting indication of 
firm strategy.   
 In this study we retain the following categories 1) no patent 2) acquisition of original 
inventor’s patent 3) acquisition of original inventor’s patent and filed complementary 
patenting 4) portfolio acquisition and filing of complementary patenting. 
 
3) Entrepreneur’s profiles 
 
3.1) Entrepreneurs identity 
Stephan and Audretsch propose a career life cycle model in which the first part of the 
academic career is focused on building a scientific reputation, while the second part is aimed 
at exploiting this reputation, cashing in being one way to transform academic capital into 
financial capital. In a large firm with well defined career paths such as the Japanese firms uses 
(Aoki 1988), similar reflection should hold true. One implication is thus that the age of 
founder matter, as they are indicators of the type of individual career strategy they adopted 
while creating a company.   
 
3.2) competence depth or scientific expertise 
As we have seen, performance of the NBF depends in good part on knowledge capture 
mechanisms that will contribute to transform founders past experience into a firm capital 
Capturing such body of knowledge and capitalise it into a start up firms suggest that previous 
experience of the entrepreneur, particularly with related research activities plays a role 
(Murray 2004). One classical variable is certainly founder’s scientific and technological 
education (both level engineer, PhD and field).  
Another variable regards the experience and status gained in the academic field. Mangematin 
recalled the importance of founders experience (Mangematin et al. 2002). He introduces a 
distinction between junior scientists - scientific and technological specialists- and senior 
 scientists – who gained more coordination and management skills. His results show that 
junior scientists tend to found category A firms – slow growth, local resources based, 
addressing local niche market- , while senior scientists rather establish category B firms –fast 
growth, attractive, research intensive, addressing broad market (Mangematin et al. 2002). 
We retained the following variables  
1) Education and status  
(1a) M.Sc 1b) M.D 1.c) pharmacist 1.d) PhD 1.e) Post doc 1.f) researcher 1.g) Associate or 
full professor) 
2) Experience  
(2.a) junior researcher 2.b) senior researcher 3c) famous researcher (adapted from 
Mangematin et al. 2002)  
3) accuracy discloses qualitative information on the field of expertise 
   
3.3) Competence visibility or signalling 
Strong uncertainty and asymmetries of information make it hard for external decision makers 
such as star scientist, venture capitalist, or fund providers to recognize the quality of the 
project of business creation. Entrepreneurs face the ‘liability of newness’: lack of resources, 
organization and reputation, uncertainty about the future. Reputation and centrality in 
networks condition access to resources in conditions of high uncertainty (Zucker et al. 1992, 
Gompers et al. 2005).  
Patenting and publishing activities are major mechanisms through which such as reputation 
and prestige is constructed (Stuart et al. 1999, Burton et al. 1999). They are also a part of 
academic high level know how: publishing and, to a lesser extent, patenting require highly 
skilled people and are part of the unique competences brought to start up by well trained 
scientists.  
 Visibility is part of the firm strategic positioning (Mangematin et al. 2002): the reputation of 
famous researchers plays a positive role for firm B - high profile, research intensive, fast 
growth- to attract resources, but no significant correlation was found with firm A.  
 
3.4) competence breadth or managerial expertise 
In science based firms, scientific and technological expertise certainly is essential. The 
specificity of NBF though is to combine such high level scientific knowledge with qualified 
business and management ones. In science based venture, such as NBF’s, establishing the 
right human capital depend on the entrepreneur own skills and competence, but also on 
his/her ability to make the right choice in terms of internal/external hiring of complementary 
people, on his relations and reputation to attract resources (Burton et al. 2002). Managerial 
skills, strategic skills and credibility can be acquired through specific experience in the 
pharmaceutical or the biomedical start ups firms. 
We retained  
1) Education  
(1a) Master of business 1b) MBA)  
2) Professional experience i.e career  
(a) researcher 2b) senior manager 2c) top manager 3) accuracy – discloses qualitative 
information about the industry).   
 
4) NBF performance 
One important aspect regards the comparative performance of NBF firms. As we noticed, 
evaluation of NBF at early stage is difficult, especially before IPO or buy out that will set a 
valuation process to them.  
 
 Several studies have identified date of creation (Gompers et al. 2005), size (Burton et al. 
1999), alliances, and cumulated level of investment (Stuart et al. 1999, Shane et al. 2003) as 
relevant indicators of performance before IPO or buy-out. Although they might follow several 
strategies, the most research intensive NBF have been found to have no sales, as they are 
involved in early stage development of drug or therapies (Mangematin et al. 2002).    
 III -  Preliminary results 
 
In the following section, we disclose preliminary results from our comparative research of 
bio-business ventures in Evry and Kobe bio-clusters. We particularly focused on what we are 
calling ‘Entrepreneurs profiles and experience’, a set of variables described in section II.  
 
[Table 3a - French ‘Entrepreneurs profiles’] 
 
Our sample confirms Mustar’s view (Mustar 2001) on the predominance of academic 
entrepreneurship in France. This result is also consistent with Mangematin’s observations 
(Mangematin et al. 2002).  
 
Government labs source and academic entrepreneurship 
Our French entrepreneurs have on average graduated as pharmacists or medical doctors and 
then pursued their studies through a PhD in immunology or molecular biology in one of the 
French prestigious research institutions such as Institut Pasteur, Institut Gustave Roussy, or 
Institut Cochin. The competence depth of these entrepreneurs is very high.  They have been 
trained for years as accomplished researchers and could both accumulate skills such as 
designing, executing and signalling advanced research programmes, and get an overview of 
world state of art and opportunities through years of research and exchange in the scientific 
community. 
  
After years of research and skills embodiment, they recognized that they control reasonably 
well a piece of unique or rare knowledge that could be transformed into novel technology and 
 therapy. They radically alter their career path to become start up CEO and develop their idea 
into a commercial product. 
  
Scientific knowledge is then accumulated and embodied by individual researchers in public 
labs and then transferred with the mobility of these individuals as entrepreneurs of the start up 
firms. This strong commitment goes with a profound influence of the inventor on the 
company organization and strategy. This modality of transfer, strongly anchored in our 
sample, seem rather outstanding as it leaves aside all other mechanisms of knowledge transfer 
such as technology transfer through contracts, or senior scientists affiliation to start ups (two 
exceptions are F2 and F4).  
 
Moving senior researchers enjoyed favourable conditions from their public researcher 
institutions to either acquire patents or exclusive licences to their inventions. Based on this 
constituted core technology at start up establishment, limited further publishing of patenting 
were observed in our sample. Patenting and publishing activities indicate different types of 
firm behaviours and types. Most firms in our sample patented one proprietary process and 
then limit their publishing and IP activities to developing potential applications to 
downstream value their invention. The limited role of ties kept with the original laboratory is 
another striking observation. Most of the companies in our sample switched to downstream 
networks of research including clinical trial hospitals, patient associations and more generally, 
research allies that would contribute to validate their therapeutic new paths. F2 provides an 
exception, in that all remains very much linked to public research labs. 
 
Globally, the breadth of entrepreneur’s competence is relatively limited to scientific activities, 
with very little experience in the industry. Most of them had years of management experience 
 as academics: they have been team leaders, programme or laboratory directors, and more 
rarely hospital managers. Compared with other public labs fellows, our academic 
entrepreneurs are characterised by two specificities: most of them had long exposure (through 
post doc usually) to US/UK prominent universities; and to other French or Foreign NBF.   
 
Taking a more detailed look at the population of founders, two distinct categories are 
observed: one classical academic career with people founding a companies between 55 and 65 
years old. This seems consistent with the career life cycle model (Audretsch et al. 1999). 
According to this model, after they have built a successful academic career, embodied unique 
cutting edge knowledge and experience on valuable technologies, they are aiming at cashing 
in during the second half of their career (Audretsch et al. 1999). A second modality of this 
career strategy is made of short cutting academic and biotech career with people in their 
forties 
 
 
 [Table 3b – Japanese ‘Entrepreneurs profiles’] 
 
In our Japanese NBF, pharmacist-managers-entrepreneurs are ruling.  
In our sample, the importance of the large diversified firm and the Japanese labour market is 
really observable. This confirms Kneller study on the role of large pharmaceutical and agro-
food R&D in Japan biomedical innovation (Kneller 2007). Our results are also consistent with 
available statistics: 57% have their source in large industrial companies, 39% from 
universities or governmental labs (JBA 2004). 
  
 Knowledge source in our Japanese sample emanates from three different origins. University 
based knowledge certainly plays a role in three of the five companies (J5,J2,J1). But by 
contrast with the French case, this is not the only source of Japanese NBF technology. On the 
5 firms in our sample, two are direct spin-off from large firms R&D (J1, J4). Finally, one 
company in our sample sources its technology mainly from foreign NBFs (J3).  
 
In our sample only one firm was founded clearly as a university start up (JE5). Only one 
entrepreneur (FE5) was also the inventor of the core technology that was exploited in his 
company. All other firms have been established by experienced managers with strong 
pharmaceutical experience. Large companies such as Kanebo, Santen, Sumitomo, Ajinomoto, 
Fujisawa involved in exploring biotechnologies within important research programs directly 
or through joint ventures framed their professional experience deeply. 
 
Our Japanese entrepreneurs have on average graduated from the best universities, private or 
national, and acquired good educations in science. Most of them are pharmacists or medical 
doctors, and sometimes obtained a PhD.  Brilliant students, they then were hired by prominent 
large Japanese companies, most often starting as industrial researcher and gradually gaining 
more managerial responsibilities and know how. Only J2 and J5 are based on prominent 
university scientist affiliation and only J5 was founded by a scientist-entrepreneur. 
  
Most of the founders have been trained for years as research / development directors or senior 
managers, a place at which they could get a good sense of the specificities of the drug 
development innovation process from concept to market, as well as an accurate knowledge 
about the quality, quantity and cost of resources required to do so. Finally, during years of 
management they learned organizing skills, both on how to efficiently interact with others and 
 efficiently organize working environment. Most could develop their expertise in recognising 
good opportunities in terms of drug seed and get used to thinking of technologies and projects 
in terms of a portfolio. More than incorporating frontier science themselves, they have learned 
to recognise it in others, and evaluate which one would represent a promising product 
candidate for the future. 
 
In cases sourced in pharmaceutical or large agro-food firm R&D, licensing or buy out of the 
property rights occurred in parallel with the large company taking a shareholder participation 
in the spin off. The start up firm continued patenting complementary aspects of the 
technology (compounds, process, targets), and published further in this area. 
 
Two firms (J2 and J5) are based on the more classical university knowledge sources. However, 
they differ from their French counterparts in their knowledge capture processes. Japanese 
scholars did not alter their university career path. They rather seized an additional possibility 
to ‘cash out’, to value the knowledge and know how they had accumulated. And indeed, J2 
and J5 are based on transfer from 4 university scholars, all of whom continued publishing and 
continued basic research at university after business creation. None of them left their 
academic jobs. 
 
So the resulting start up firms are places of intermediation between the academic and the 
industrial world, in which the knowledge transfer mechanism relies centrally on organizing a 
relevant division of labour with part time academics transferring their knowledge and an 
industrial drug development team. Complementarities include involvement of academics in 
publishing, co-patenting and further researching while managers of the start up take care of 
product development, industrial application and commercial transactions. These start-up firms 
 are in all cases administrated by professional managers, working as some kind of ‘business 
coach’ of the academic researchers from which they capture the core technology. 
 
The performance of our Japanese companies is impressive: most of them are following a fast 
growth trajectory with a large financial support. Most of them envisioned IPO as a mid term 
exit.  
 
Sampled companies are 4 years old, in average younger than our French sample (5 years old). 
In terms of performance it means that we should expect that the French sample exhibits larger 
companies, with more important funds rose. Actually, the reverse is true. Average employees 
for the French sample is 15, and 29 for the Japanese sample, which is a considerable size 
difference, of almost double growth.  
 
In terms of funding patterns, most Japanese firms received grants or subsidies from the 
Government as their French counterpart, important differences are visible in the allocation of 
money to early start ups by private firms. While only two French companies had raised 
private venture capital funds, all Japanese companies had done so. For spin off firms, seed 
money and participation of the mother large firm favoured this cumulative virtuous circle. 
Most of our Japanese companies had some large pharmaceutical or first generation biotech as 
shareholders.  Capital rose ranked from 500 000 euros for the smallest, to 27 million euros. If 
we except JE5, Japanese companies rose between 10 million to 27 million euros (while the 
most effective fund raising firm in the French sample only reached 8 million euros) in 2007.  
 
Finally, most companies in our sample have developed very robust strategic alliances. 
Conversely to most French firms, they first kept very strong ties with their knowledge 
 sourcing institutions: spin off firms kept strong links with their mother firm (J1, J4, J3), and 
Start up firms with their originating universities. Most of them also established links with 
Competing NBF abroad. Finally, as was the case of France, companies developing innovative 
new science based therapies established links with university/ hospital/ patients organizations 
for clinical trial and application purposes (J2, J5). 
 
These two trajectories are both really dominating in our Kobe/ Evry comparison, and at the 
same time are closely connected to the differences between the two countries’ national 
systems of innovation.  
 
[Table 4 -  Summary table – comparative analysis of Japanese and French NBF] 
 
The result of this investigation confirmed that NBF entrepreneurship follows important 
variations depending on the country considered. In our France sample, almost all of the 
entrepreneurs were found to be ‘academic entrepreneurs’--a term used in regards to senior 
scientists who left their public research positions to take the lead of the start-ups they founded. 
By contrast, in our Japan sample, company foundation came from two sources: previous 
managers of the pharmaceutical industry, and academics. Strikingly, in Japan no university 
researcher left his/her public position to become an academic entrepreneur, and leadership of 
the firm was exerted by experienced industrial managers. 
 
In our sample, sources of entrepreneurship vary strongly from one sample to the other, as does 
the knowledge capture mechanisms used: founders do not have the same experience and do 
not create the same kind of organisation.  
 
 These differences invite us to articulate individual behaviours of entrepreneurs in the wider 
national system of innovation in which they take place. More specifically, it refers to barriers 
and incentives to bio-business creation in the two countries.  In other words, the construction 
of ‘bio-entrepreneurs’ are embedded in wider societal elements (Lanciano et al. 1992). The 
nature of the institutional gap between university and industry (Lehrer and al. 2004, Gittelman 
2006), and the emergence of a novel organisation to build a bridge between them, follows a 
very country specific path. 
   
IV -  Discussion and conclusion 
 
There is a large consensus that New Biotechnology Firm creation represents an important 
challenge for country innovativeness, specifically in the biomedical field (Ibata-Arens 2005). 
International comparative studies are still scarce, and many of them share a common 
assumption that countries performance in this respect should be benchmarked against the US 
model where NBF entrepreneurship originated (Ernst and Young 2005). Recently, pioneering 
work have pointed that NBF creation is part of a wider institutional picture that need to be 
considered for comparison purposes (Lehrer et al 2004, Casper 2006, Gittelman 2006, Kneller 
2007). In addition, very limited data and studies are available to date to pursue this ambitious 
research agenda.     
 
Our research objective is to contribute to this research programme by deepening our 
understanding of NBF entrepreneurship in Japan and France. Against the US benchmark, 
Japan and France have been classified as poorly performing in taking advantage of the new 
biotechnology paradigm. Our study invites to somewhat more elaborated and longer term 
analysis as it confirms that NBF creation is not a universal or stand alone economic action, 
 but one that is deeply embedded in a wider national system of innovation. Comparisons 
mutatis mutandis of rates of creation thus require more in depth understanding in order to be 
properly interpreted. Although through a limited number of cases, the comparison we made 
already clearly indicates that NBF ‘entrepreneurs’ in France do not have the same background, 
experience and motivation as their Japanese counterparts. Beyond our samples, available data 
and statistics suggest that these results should hold true at country level. Our findings reflect 
many very differences pointing to two crucial elements in understanding NBF creation:  
-the organisation of professions and careers in the biomedical field (Lanciano et alii 1992),  
-the organisation of national systems of biomedical research and innovation (Kneller 2007).  
 
In this final section, we would like to come back on two main findings and discuss their 
interpretation and implications. 
 
In this paper, we have presented the result of a comparative study performed about drug 
discovery start up firms in Kobe, Japan and Evry, France. Representativity of our sample 
needs to be confirmed in the future and certainly be established on a larger scale, although 
available statistics from French and Japanese Biotech Trade Associations are consistent with 
our samples. In addition recent studies seem to confirm the observed trends: the importance of 
academic entrepreneurship in France and the comparative weight of large companies spin-offs 
in Japan (Ibata-Arens 2005; Mustar 2001), as well as important institutional and incentive 
obstacle to academic mobility (Motohashi 2004).The results clearly indicates that biographies 
of entrepreneurs and business creation experience exhibits very contrasted patterns in Japan 
and France.  
 
 French academic-entrepreneurs were ‘cashing in’ years of public research discoveries. In the 
interviews, several of them considered that NBF constituted the right vehicle to do so, as 
compared with their original research institutes or universities.  
 
As Lehrer et al. (2004) described, they are enjoying a full consistent organisation to help them 
push their discovery into a practical cure or compound. Their model of commitment is then 
very important and they usually took the lead of the NBF and left their position in the public 
sector. Since 1999 – and the law on innovation- in France, the career risk associated with this 
behaviour is relatively limited as they could return to their public research position in case of 
failure.  
 
This pattern conveys several implications at a national/ industrial level. First, the 
performances of the NBF are limited, especially as regards growth and employment. This is 
consistent with observations that academic start ups grow more slowly than others (Audretsch 
and Stephan 1999). Second, as a bridging institution with the organisational role of feeding 
large pharmaceutical companies portfolios, this pattern might also bear some limits due in 
part to its focus on academic competences.   
 
Japanese entrepreneurs exhibit a hybrid model. One key finding is the limited commitment 
university professors took in all but one case. So one question naturally follows: would 
professors in Japan show a more limited interest in ‘cashing in’ than their US counterparts? 
Or would they be less interested than French researchers in having an NBF as an 
organisational vehicle to apply their discoveries into practical compound or cure? This is 
doubtful. 
 
 The Japanese government has considerably reformed the academic and national university 
status in recent years to favour the creation of NBF by academics. For instance, since 2000, 
like in France, Japan’s academics are officially authorised to take part in a commercial 
activity without losing their jobs. One workable line of explanation could be that of 
acceptability and professional norms. Life time employment and very close social control are 
important features of Japanese organisations (Lehrer et al. 2004). In addition to the legal 
contract, academics are bound by more informal mutual commitment with their peers, as these 
peers control academic careers (Lehrer et al. 2004). How well would individual initiatives of 
cashing-in be perceived by other academic members? How acceptable would it be for peers 
that one of them spends its time for private rather than collective purposes?  
 
A second key finding is the importance of founders coming from pharmaceutical companies. 
This is really unexpected, as most of the literature and policy making, including in Japan, are 
stressing academic entrepreneurship as a major target (in Japan, the Government targeted 
1000 such academic bio-ventures by 2010 according to Lehrer et al. 2004). We see two main 
lines of analysis of this finding.  
 
One is consistent with Burton et al (2002) idea that large organisations generate their own 
competition. This idea applies here. After years of considerable profits and relative industrial 
stability during which they importantly invested in R-D projects and bio-technology transfer 
from the US, Japanese pharmaceutical industry has reorganised deeply and divested. For 
some Japanese managers this meant a break in the lifetime employment model and/or 
important opportunities to buy promising projects for cheap prices. In our sample, this has 
been a major motivation and source of NBF creation.  
 
 The other refers to the larger societal context of Japan, and the role of large corporations in 
the Japanese economy (Lehrer et al. 2004). In a recent analysis, Kneller (2007) has shown that 
large pharmaceutical companies have largely orchestrated the transfer of emerging US 
biotechnologies to their internal R-D in an ‘autarkic’ manner i.e. as the central integrative 
organization of innovation. This is consistent with the appropriation mechanisms of 
technology long observed in Japan (Lanciano et al 1992) and more widely consistent with 
observations made earlier about Japan NIS (Freeman 1987). Thus, the very important 
presence of large pharmaceutical company managers in NBF creation might well be the 
Japanese way of appropriating biotechnology and constructing entrepreneurship.  
 
This pattern of entrepreneurship in turn has implications at the national level. First, the low 
involvement of academics in business creation might well limit the opportunities for NBF 
creation from university discoveries, which are considered by many as a rich source of drug 
discovery firms. On this side, some important changes are on going, and the situation might 
evolve in the future. Second, the strong presence of large pharmaceutical managers should 
ease the establishment of strong links with them. Our samples seem to indicate this, as several 
such companies have benefited from investments by their ‘mother’ companies. On the other 
hand, a recent study by Kneller (2007) points to the relative weakness of the ties between 
large pharmaceutical firms and Japanese biotech start ups. Further investigations seem 
necessary to clarify this point.              
 
It is our understanding that ‘entrepreneurs’ are shaped by long lasting societal dimensions. In 
this regard, we believe, this paper contributes to departing from a unique and universal view 
about ‘NBF entrepreneurs’ as a simple extension of the US case. If this finding is convincing 
 enough, it then is an invitation for further and more systematic research on the societal 
shaping of NBF entrepreneurial activities.         
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 Table 1: Overall picture of Japan and France biotech fields 
 
2006 US JAPAN FRANCE 
Number of biotech 1452 586 420 
Number of biomedical - 250 172 
Number of public Cies 336 12 11 
Av. size 89 16 9 
Share of R&D staff - 44 68 
 
Source: JBA 2005, 2007; France-biotech 2007  
 Table 2a: List of French NBF 
 
Name Date of 
creation 
Technology Target Number of 
employee 
F1 2001 Cell therapy Urology 20 
F2 2006 Cell therapy HIV 6 
F3 2000 molecular biology and 
diagnostic, target 
identification 
Obesity, Diabetes, 
schizophrenia, 
autism 
34 
F4 1999 Monoclonal Antibody Cancer (pancreas, 
liver) 
20 
F5 2002 molecular biology and 
diagnostic 
Cancer,  
Orphan genetic 
diseases 
8 
F6 2004 Immunology,  
proteomics 
genetic engineering 
Functional animal 
models 
7 
 
  
 Table 2b: List of Japanese NBF 
 
Name Date of 
creation 
Technology Target Number of 
employee 
J1 2000 Gene therapy, 
molecular biology 
CNS stroke 
regeneration,  
head Cancer 
30 
J2 2005 (2000) tissue engineering Corneal tissue, 
bone regeneration 
33 
J3 2002 Cell therapy  
tissue engineering 
Diabetes, 
muscular 
dystrophy, 
myocardial and 
cerebral infarcts. 
25 
J4 2003 Gene therapy, 
proteomics 
(Drug Targets) 
cancer, arthritis, 
dermatitis 
45 
J5 2003 Recombinant vaccine, 
gene therapy 
Cancer 12 
 
 
 
 
 
 
 
 
 
 
  
  
Table 3a: French ‘Entrepreneurs Profiles’ 
 
Identity Competence Depth Competence 
visibility 
Competence breadth 
Na
me 
age sexe status Education Experience accuracy publishing patenting pharma biotech 
 
F1 
 
 
55 M CEO 
then 
CSO 
Med. D. 
Post doc 
Researcher 
Lab. Dir 
 
Senior 
researcher 
Muscle cell 
biol. 
 
Published 
Linked 
X Patented 
(Proprietary 
process) 
X X 
F2 65 M CSO Med D. 
PhD biol 
Post Doc 
Assistant 
MCF 
Lab Dir. 
Dpt Dir. 
 
Senior 
researcher 
with 1st 
rank 
internation
al 
publication
s 
Protein/P 
Interaction 
Mol. Biol., 
Mol. Vir. 
 
Published 
large number 
Quality 
linked 
Large 
Publishing 
going on (on 
new therapy/ 
application) 
 
Patented 
+In-
Licensing 
from allied 
lab 
(proprietary 
molecule/ 
targets) 
X Serial 
entrepreneur 
F3 
 
 
 
 
 
45 M CSO PhD Biol 
Post docs 
Team 
leader 
 
Senior 
researcher 
Diabetes, 
Genomics 
 
Published 
little 
Partially 
linked 
Little 
Publishing 
(on 
application)  
 
Patenting  
portfolio 
(proprietary 
process)+ 
in & out-
licensing 
(gene 
targets) 
X Serial 
researcher 
F4 
 
 
 
 
 
65 M CEO Pharmacist 
PhD 
  
Researcher Immunology 
Monoclonal 
Antibody 
publishing 
on new 
technological 
path/ therapy 
Patenting 
portfolio 
(proprietary 
process)+ 
patenting+ 
in-licensing 
(on specific 
applications
Hospital 
Consultant 
Senior 
manager 
Prominent 
Company 
Entrepreneur  
 ) 
F5 
 
 
 
 
 
 
 
40 M CEO 
CSO 
PhD Biol. 
Post doc 
 
Researcher Biosensors 
Mol. Biol. 
X Patented 
(proprietary 
process) 
+in-
licensing 
(on specific 
disease 
application) 
X Serial 
researcher 
F6 
 
 
 
 
 
 
40 M CEO Med.D 
PhD 
Post doc 
Researcher 
 
Senior 
Researcher 
Immunology 
Biol. Mol. 
Cancer res. 
 
Published 
quality  
linked 
 
X Unpatented 
(proprietary 
process) 
Hospital X 
 
 
 
 
Caption for Table 3a: French ‘Entrepreneurs Profiles’: 
Source: interviews and firm documentation 
 
 
 
 
 
 
  
  
Table 3b: Japanese ‘Entrepreneurs Profiles’ 
 
Identity Competence Depth Competence visibility Competence breadth 
Name Age sex status Education Experienc
e 
Accuracy publishing patenting Pharma biotech 
J1 
 
57 M CEO Pharmacist 
PhD bio 
Post doc 
Associate 
 
Senior 
Researche
r 
DNA 
replicatio
n 
Cancer 
research 
 
Published 
Linked 
Little 
Publishing 
(on new 
therapy/ 
application)+ 
scientist 
publishing at 
university 
Buy + 
patenting 
portfolio 
(proprietary 
molecule, 
targets, 
process) 
Research 
Director 
Dept 
 
X 
J2 46 M CEO Pharmacist 
PhD 
Researcher 
 
Researche
r 
Cell 
Differenti
ation 
Enzymol. 
 
X 
Scientist 
publishing at 
their 
universities 
Co-patenting 
portfolio 
(tissue 
engineering 
process) 
Research 
Development 
Senior 
management 
 
Researcher 
VC director 
Serial 
entrepreneur 
 
J3 
 
 
 
 
 
60 M CEO 
Pdt 
Pharmacist 
 
X X Little 
publishing 
In-licenced 
portfolio 
mother bio-
venture 
platform 
(proprietary 
cell 
engineering 
process)+ in 
licencing 
(cell 
engineering 
process) 
Patents, legal 
Management 
Senior 
manager 
Senior 
manager 
 
J4 
 
 
 
 
 
51 M CEO 
Pdt 
Master 
chemistry 
X Med. 
Chem 
Published 
Linked 
Publishing 
(on new 
therapy/ 
application) 
Buy+Patenti
ng portfolio 
(proprietary 
molecule / 
target) 
R&D 
Director 
X 
 J5 
 
 
 
 
 
 
 
50 M Board M. D. 
PhD 
Post Doc 
Associate 
Professor 
 
Famous 
researcher 
Gene 
therapy 
Published 
X 
Scientists 
publishing at 
their 
university 
(on novel 
therapy 
application) 
Co-Patenting 
(molecule/ 
therapy 
process) 
X X 
 
 
 
Caption for Table 3b: Japanese ‘Entrepreneurs Profiles’ 
Source: interviews and firm documentation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
Table 4 - Summary – comparative analysis of Japanese and French NBF 
 Knowledge capture Entrepreneur profiles 
Knowledge 
source 
Knowledge 
Capture 
Knowledge 
Appropriation 
Competence 
Depth 
Competence 
visibility 
Competence 
breadth 
French NBF 
 
Public research 
(GRI) 
Researcher 
mobility 
Original patent 
acquisition (Sr 
Researcher 
Patent) 
 high in 
academia 
Limited Limited 
 
 
Japanese NBF University 
 
 
 
Pharmaceutical 
 
 
Researcher 
affiliation 
 
 
Team mobility 
 
 
Co-patenting 
 
 
 
Buy+ cont. 
patenting 
 
 
limited in 
academia 
 
 
High in large 
firm R&D 
 
 
Large through 
scholars 
 
 
Large with 
scholars 
 
 
Large with 
industry Sr 
managers 
 
Large with 
industry Sr 
manager 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Caption for Summary – Comparative analysis of Japanese and French NBF 
Source: interview and firm documentation 
 
